My investment advice source says:
"Doxorubicin is projected to do $1.3B US annual sales in 2024 at $60 per treatment. This combination could increase the price to $4,000 US per treatment."
My arithmetic says, if we have to share the $4,000 50-50 with BP then that's $43B US annual sales!
If BP buys us, they keep all of the sales and that's incremental $85B in annual sales! (that's incremental ANNUAL SALES!!!!)
Ann: Breakthrough Zantrene Heart Protection Discovery, page-82
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
0.055(3.59%) |
Mkt cap ! $270.1M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.60 | $1.53 | $79.91K | 51.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 23239 | 1 |
View Market Depth
| Last trade - 16.10pm 17/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |